ATE231398T1 - Verwendung von zyklodextrine zur modulierten genexpression mit reduzierter immunostimulation - Google Patents
Verwendung von zyklodextrine zur modulierten genexpression mit reduzierter immunostimulationInfo
- Publication number
- ATE231398T1 ATE231398T1 AT96928899T AT96928899T ATE231398T1 AT E231398 T1 ATE231398 T1 AT E231398T1 AT 96928899 T AT96928899 T AT 96928899T AT 96928899 T AT96928899 T AT 96928899T AT E231398 T1 ATE231398 T1 AT E231398T1
- Authority
- AT
- Austria
- Prior art keywords
- cyclodextrins
- gene expression
- reduced
- modulated gene
- reduced immunostimulation
- Prior art date
Links
- 230000003308 immunostimulating effect Effects 0.000 title abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 2
- 229940097362 cyclodextrins Drugs 0.000 title 1
- 230000014509 gene expression Effects 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nanotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/527,126 US6667293B1 (en) | 1995-09-12 | 1995-09-12 | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
| PCT/US1996/013311 WO1997010005A2 (en) | 1995-09-12 | 1996-08-19 | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE231398T1 true ATE231398T1 (de) | 2003-02-15 |
Family
ID=24100201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96928899T ATE231398T1 (de) | 1995-09-12 | 1996-08-19 | Verwendung von zyklodextrine zur modulierten genexpression mit reduzierter immunostimulation |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6667293B1 (de) |
| EP (1) | EP0850070B1 (de) |
| JP (1) | JPH11512426A (de) |
| AT (1) | ATE231398T1 (de) |
| AU (1) | AU6848596A (de) |
| CA (1) | CA2231687A1 (de) |
| DE (1) | DE69625919T2 (de) |
| DK (1) | DK0850070T3 (de) |
| ES (1) | ES2187670T3 (de) |
| WO (1) | WO1997010005A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6667293B1 (en) * | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
| JP2003507345A (ja) * | 1999-08-10 | 2003-02-25 | エムエル ラボラトリーズ ピーエルシー | デキストリン溶液を使用した治療薬剤の送達方法 |
| TWI321054B (en) * | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
| US6624358B2 (en) * | 2001-12-13 | 2003-09-23 | Andrew Corporation | Miniature RF coaxial cable with corrugated outer conductor |
| ES2377318T3 (es) | 2002-09-06 | 2012-03-26 | Cerulean Pharma Inc. | Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos |
| KR20050051686A (ko) * | 2002-10-09 | 2005-06-01 | 인설트 테라페틱스, 인코퍼레이티드 | 사이클로덱스트린-기초한 재료, 조성물 및 이의 용도 |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| WO2009048947A1 (en) * | 2007-10-09 | 2009-04-16 | Board Of Regents, The University Of Texas System | Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors |
| US9572895B2 (en) | 2010-08-06 | 2017-02-21 | The Board Of Trustees Of The University Of Illinois | Multiplexed supramolecular assemblies for non-viral delivery of genetic material |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| US5068227A (en) * | 1989-01-18 | 1991-11-26 | Cyclex, Inc. | Cyclodextrins as carriers |
| US5149798A (en) | 1989-04-06 | 1992-09-22 | Worcester Foundation For Experimental Biology | Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses |
| US5248670A (en) | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5691316A (en) * | 1994-06-01 | 1997-11-25 | Hybridon, Inc. | Cyclodextrin cellular delivery system for oligonucleotides |
| US6667293B1 (en) * | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
-
1995
- 1995-09-12 US US08/527,126 patent/US6667293B1/en not_active Expired - Fee Related
-
1996
- 1996-08-19 EP EP96928899A patent/EP0850070B1/de not_active Expired - Lifetime
- 1996-08-19 DK DK96928899T patent/DK0850070T3/da active
- 1996-08-19 ES ES96928899T patent/ES2187670T3/es not_active Expired - Lifetime
- 1996-08-19 CA CA002231687A patent/CA2231687A1/en not_active Abandoned
- 1996-08-19 WO PCT/US1996/013311 patent/WO1997010005A2/en not_active Ceased
- 1996-08-19 AT AT96928899T patent/ATE231398T1/de not_active IP Right Cessation
- 1996-08-19 AU AU68485/96A patent/AU6848596A/en not_active Abandoned
- 1996-08-19 DE DE69625919T patent/DE69625919T2/de not_active Expired - Lifetime
- 1996-08-19 JP JP9511954A patent/JPH11512426A/ja not_active Ceased
-
2002
- 2002-10-23 US US10/278,429 patent/US20030148981A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6667293B1 (en) | 2003-12-23 |
| DK0850070T3 (da) | 2003-04-22 |
| CA2231687A1 (en) | 1997-03-20 |
| DE69625919T2 (de) | 2004-01-15 |
| WO1997010005A2 (en) | 1997-03-20 |
| AU6848596A (en) | 1997-04-01 |
| WO1997010005A3 (en) | 1997-06-26 |
| EP0850070B1 (de) | 2003-01-22 |
| EP0850070A2 (de) | 1998-07-01 |
| DE69625919D1 (de) | 2003-02-27 |
| ES2187670T3 (es) | 2003-06-16 |
| US20030148981A1 (en) | 2003-08-07 |
| JPH11512426A (ja) | 1999-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE185597T1 (de) | Methode zur modulation der genexpression mit reduzierter immunstimulierender wirkung | |
| ATE236248T1 (de) | Verfahren zur verwendung von oligonukleotiden mit modifizierten cpg dinukleosiden | |
| ATE231398T1 (de) | Verwendung von zyklodextrine zur modulierten genexpression mit reduzierter immunostimulation | |
| BR0011000A (pt) | Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico | |
| GR3020557T3 (en) | Oligonucleotide alkylphosphonates and alkylphosphonothioates. | |
| DE69931377D1 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
| NO965080D0 (no) | Antisens oligonukleotidmodulering av genekspresjon | |
| EP0831848A4 (de) | Verfahren zur behandlung von lungenkrankheiten unter verwendung von antisense-oligonukleotiden | |
| CA2229811A1 (en) | Inverted chimeric and hybrid oligonucleotides | |
| EP1325019A4 (de) | Antisense-modulation der clusterinexpression | |
| DE69637660D1 (de) | Verfahren zür einführung und expression von genen in tierischen zellen | |
| ATE207356T1 (de) | Verwendung von tiagabin zur behandlung von schlafstörungen | |
| BR9106440A (pt) | Oligonucleotideo ou analogo de olifonucleotideo e processo para tratar um animal suspeito de ter uma doenca que se caracteriza pela expressao de gene tat de hiv | |
| DE69513998D1 (de) | Verwendung von 2'-substituierten oligonukleotiden zur reduzierung der genexpression | |
| DE69620906D1 (de) | Antisense-oligonukleotidmodulation der raf-genexpression | |
| EP1123414A4 (de) | Antisense modulation der expression von integrin alpha 4 | |
| EP1430072A4 (de) | Antisense-modulierung der expression des cholesterylestertransferproteins | |
| EP1250347A4 (de) | Antisense modulation der akt-3 expression | |
| PT1237562E (pt) | Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas | |
| EP1185696A4 (de) | Modifikation der expression der menschlichen proteinkinase c-delta mit hilfe von antisense-oligonukleotiden | |
| EP1173458A4 (de) | Antinsens modulierung der sra expression | |
| ATE260108T1 (de) | Verwendung von citicoline zur behandlung von multipler sklerose | |
| ATE302605T1 (de) | Tazaroten und uvb-phototherapie zur behandlung von psoriasis | |
| ATE235908T1 (de) | Verwendung von pentosan polysulfat zur behandlung von narben in chronischer fortschreitender gefässerkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0850070 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |